Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 12,82 € (+22,56 %). Medianen er 13,15 € (+25,72 %).
| Køb |
9 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Cellebrite plans to relocate corporate headquarters from Israel to the US
Cellebrite’s board has approved a restructuring that would place a new US parent company at the top of the group’s corporate structure. The move is subject to shareholder and regulatory approval and is expected to be completed by H1 2027. CEO Shiv Ramji cites growth in key markets, greater attractiveness to investors and possible index inclusion as reasons; further details will be disclosed via SEC filings. » Mere på de.investing.com
Cellebrite brings AI tool Genesis to enterprises and expands international availability
Cellebrite is making its AI-powered investigation tool Genesis generally available to enterprises and is expanding the market to countries such as Australia, the United Kingdom and soon the EU. Genesis, which has already been used by law enforcement since June 2026, is now intended for internal investigations such as employee misconduct, financial fraud, M&A due diligence, insider threats and compliance. At the same time, the company is introducing the Deep Investigator feature to extract hard-to-access mobile data and plans to add additional features and data sources in the coming months. » Mere på de.investing.com
Cellebrite DI: 30% sell-off as entry opportunity, JPMorgan sees over 40% potential
Cellebrite DI was punished by more than 30% at times after the Q2 results and the surprise CEO change, but is being viewed as a buying opportunity. Criticisms include longer sales cycles and slower monetization progress on product updates, while the core story remains intact according to the report. JPMorgan sees more than 40% upside; the price-to-sales (P/S) ratio is below 5 after the pullback and Shiven Ramji takes over the CEO role immediately. » Mere på finanzen.net
Cellebrite DI falls to 52-week low despite strong metrics
Cellebrite DI shares fell to 10.01 USD, reaching a new 52-week low, despite a roughly 9% gain over the past 12 months. Analysts at InvestingPro currently view the stock as undervalued with significant upside potential. The company reports high gross profit margins of 83.9% and more cash than debt, and beat expectations in Q1 2026 with EPS of 0.12 USD; revenue was 128.3 million USD. TD Cowen reaffirmed its buy rating and set a price target of 23 USD. » Mere på de.investing.com
Cellebrite technology used by Russia to extract data from opposition iPhone after sales ban
University of Toronto’s Citizen Lab and legal records show Russian investigators used Cellebrite’s UFED to access opposition politician Andrey Pivovarov’s iPhone in June 2021, months after Cellebrite said it stopped sales to Russia. Evidence suggests the device extracted contacts and messages tied to Open Russia and contributed to subsequent surveillance and phishing operations against dissidents. Cellebrite says post‑March 2021 use is unauthorized and legacy hardware would lack support, while critics call for stronger legal and technical controls including a killswitch. » Mere på forbes.com
Virksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 114,9 mio. | 19,56 % |
| Bruttofortjeneste | 92,82 mio. | 14,44 % |
| Nettoresultat | 5,58 mio. | 66,22 % |
| EBITDA | 14,49 mio. | 44,03 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 2,9 mia. € |
Antal aktier | 251,34 mio. |
Højeste/laveste i 52 uger | 18,12 € - 8,69 € |
| Udbytte | Nej |
Beta | 1,05 |
P/E (PE Ratio) | 53,95 |
PEG (PEG Ratio) | 0,62 |
K/I (PB Ratio) | 5,84 |
P/S (PS Ratio) | 6,21 |
Virksomhedsprofil
Cellebrite DI Ltd. udvikler løsninger til retligt godkendte efterforskninger. Dets DI-platform gør det muligt for brugere at indsamle, gennemgå, analysere og administrere digitale data gennem hele efterforskningsforløbet i forbindelse med retligt godkendte efterforskninger, og løsningerne anvendes i en række forskellige sager, herunder børneudnyttelse, drab, antiterror, grænsekontrol, seksualforbrydelser, menneskehandel, virksomhedssikkerhed, tyveri af intellektuel ejendom og civile retssager. Virksomhedens Universal Forensic Extraction Device-løsning løser problemer med adgang til digitale oplysninger, herunder komplicerede enhedslåse, krypteringsbarrierer, slettet og ukendt indhold samt andre forhindringer, der kan forhindre afgørende beviser i at komme frem i lyset. Den tilbyder også Seeker-løsningen, som giver mulighed for at analysere videooptagelser; OSINT Analyze, en realtidsdybdeanalyseløsning, der bruges til at analysere åben kildeinformation, såsom overfladeweb, deep web og dark web; og Crypto Tracer, som analyserer blockchain-transaktioner sammen med relaterede data fra en omfattende liste af kilder for at identificere og kategorisere wallets og transaktioner. Virksomheden betjener føderale, delstatslige og lokale myndigheder samt virksomheder og tjenesteudbydere. Den har aktiviteter i USA, Tyskland, Singapore, Australien, Brasilien, Storbritannien, Frankrig, Canada, Japan og Indien. Virksomheden blev stiftet i 1999 og har hovedkontor i Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. fungerer som datterselskab af Sun Corporation.
| Navn | CELLEBRITE DI LTD |
| CEO | Shiv Ramji |
| Hjemsted | Petah Tikva,
hm Israel |
| Websted | |
| Branche | Sundhedsteknologi |
| Børsnotering | 06.11.2020 |
| Medarbejdere | 1.285 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | CLBT |